<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358329</url>
  </required_header>
  <id_info>
    <org_study_id>P500-0717</org_study_id>
    <nct_id>NCT03358329</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)</brief_title>
  <official_title>The ENCORE Study: Safety Evaluation of Repeat Placement of the Corticosteroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intersect ENT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intersect ENT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ENCORE Study is designed to evaluate the repeat administration of the S8 Sinus Implant in
      chronic sinusitis (CS) patients with recurrent nasal polyps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ENCORE Study is a prospective open-label, non-randomized, multicenter study in CS
      patients who had undergone prior endoscopic sinus surgery (ESS) including bilateral total
      ethmoidectomy and present with bilateral ethmoid polyposis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2017</start_date>
  <completion_date type="Actual">January 17, 2019</completion_date>
  <primary_completion_date type="Actual">January 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Implant-Related Serious Adverse Events</measure>
    <time_frame>365 days</time_frame>
    <description>Evaluated via tabulation of implant-related serious adverse events (SAE) reported by subjects between consent and Day 365.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-22 Total Score</measure>
    <time_frame>Baseline, 90 days, 180 days</time_frame>
    <description>Sino-Nasal Outcomes Test (SNOT-22) is a validated disease-specific symptom-scoring instrument consisting of 22 questions, each scored on a 6-point scale of 0 (no problem) to 5 (probably as bad as it can be) based on the subject's recollection of symptoms over the past 2 weeks. The total score ranges from 0 to 110, with a higher score reflecting greater symptom burden. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value from baseline. Negative values for change from baseline indicate reduction (improvement) in sino-nasal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Obstruction/Congestion Score</measure>
    <time_frame>Baseline, 90 days, 180 days</time_frame>
    <description>Determined on a scale of 0 (no symptoms) to 3 (severe symptoms) based on the subject's recollection of symptoms over the past week using a reflective paper questionnaire. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value at baseline. Negative values for change from baseline to follow-up indicate reduction (improvement) in nasal obstruction/congestion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Sinusitis</condition>
  <condition>Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>S8 Sinus Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>S8 Sinus Implant</intervention_name>
    <description>In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses</description>
    <arm_group_label>S8 Sinus Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has provided written informed consent using a form approved by the reviewing
             institutional review board (IRB) and sponsor.

          2. Patient is ≥ 18 years of age.

          3. Patient is willing and able to comply with protocol requirements.

          4. Patient has a confirmed diagnosis of CS with nasal polyps, as defined in the 2016
             &quot;International Consensus Statement on Allergy and Rhinology&quot;.

          5. Patient has undergone prior ESS including bilateral total ethmoidectomy at least 90
             days prior to screening.

          6. Patient has evidence of bilateral ethmoid sinus obstruction due to polyposis
             warranting intervention (polyp grade ≥ 2 on each side).

          7. Patient is able to tolerate daily use of Mometasone Furoate Nasal Spray (MFNS).

          8. Patient is able to tolerate topical/local anesthesia.

          9. In the opinion of the investigator, patient's ethmoid sinus anatomy is amenable to
             in-office bilateral placement of the S8 Sinus Implant (i.e., able to pass into the
             middle meatus on both sides the S8 Sinus Implant with 20 mm in nominal length and 7 mm
             in compressed diameter).

         10. Female patients of reproductive potential must not be pregnant or nursing and must
             agree to not become pregnant during their participation in the study.

         11. Female patients of childbearing potential must agree to use consistent and acceptable
             method(s) of birth control during their participation in the study.

        Exclusion Criteria:

          1. Patient has extensive ethmoid sinus polyp grade (grade 4 on at least one side).

          2. Patient has extensive adhesions/synechiae (grade 3 or 4).

          3. Patient has used parenteral and injected steroids (e.g., Kenalog injection) during 30
             days prior to the baseline procedure.

          4. Patient has used oral steroids, budesonide or other sinus steroid irrigations/rinses,
             nebulized steroids administered nasally or budesonide drops during 14 days prior to
             the baseline procedure.

          5. Patient has oral-steroid dependent condition such as chronic obstructive pulmonary
             disease (COPD) or asthma.

          6. Patient has known history of allergy or intolerance to corticosteroids or mometasone
             furoate.

          7. Patient has used monoclonal antibodies for asthma, allergies or nasal polyps (e.g.,
             Dupixent, Nucala, Xolair) during 30 days prior to the baseline procedure.

          8. Patient requires monoclonal antibodies for asthma, allergies or nasal polyps during
             the duration of the study.

          9. Patient has presence of physical obstruction that would preclude access and placement
             of the S8 Sinus Implant in the middle meatus (e.g., severe septal deviation, septal
             spur, very small middle meatus, total obstruction of the sinonasal passage with severe
             adhesion, scarring, polypoid edema or polyps).

         10. Patient has known history of human immunodeficiency virus (HIV) or immunoglobulin G or
             A subclass deficiency.

         11. Patient has clinical evidence of acute sinusitis (AS), as defined in the 2016
             &quot;International Consensus Statement on Allergy and Rhinology&quot;.

         12. Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone
             erosion on prior computed tomography (CT) scan, necrotic sinus tissue).

         13. Patient has evidence of severe concomitant disease or condition expected to compromise
             survival or ability to complete assessments during the 365-day study follow-up period
             (e.g., cancer).

         14. Patient is currently participating in another clinical study.

         15. Patient has previously undergone ESS and experienced a cerebrospinal fluid (CSF) leak
             or has residual compromised vision as a result of a complication in a prior ESS
             procedure.

         16. Patient has known dehiscence of the lamina papyracea.

         17. Patient has evidence of active tuberculosis or active viral illness (e.g., ocular
             herpes simplex, chickenpox, measles).

         18. Patient has known history or diagnosis of glaucoma or ocular hypertension (prior
             ocular exam with intraocular pressure of &gt;21 mmHg and pressure lowering medication
             given) or posterior subcapsular cataract.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Manes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sacramento ENT</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT &amp; Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Surgical Specialists</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BreatheAmerica of Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison ENT</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose and Throat Associates</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>29025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgerland Clinical Research</name>
      <address>
        <city>North Logan</city>
        <state>Utah</state>
        <zip>84341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>November 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2019</results_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>corticosteroid</keyword>
  <keyword>implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03358329/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03358329/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 10 sites across the US between November 2017 and January 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>S8 Sinus Implant</title>
          <description>Corticosteroid-eluting Sinus Implant with 1350 mcg of MF
Mometasone furoate nasal spray (200 mcg) once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>S8 Sinus Implant</title>
          <description>Corticosteroid-eluting Sinus Implant with 1350 mcg of MF
Mometasone furoate nasal spray (200 mcg) once daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SNOT-22</title>
          <description>Sino-Nasal Outcomes Test (SNOT-22) is a validated disease-specific symptom-scoring instrument consisting of 22 questions, each scored on a 6-point scale of 0 (no problem) to 5 (probably as bad as it can be) based on the subject's recollection of symptoms over the past 2 weeks. The total score ranges from 0 to 110, with a higher score reflecting greater symptom burden. Negative values for change from baseline indicate reduction (improvement) in sino-nasal symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nasal Obstruction/Congestion ≥ 2</title>
          <description>Determined on a scale of 0 (no symptoms) to 3 (severe symptoms) based on the subject's recollection of symptoms over the past week using a reflective paper questionnaire. Negative values for change from baseline to follow-up indicate reduction (improvement) in nasal obstruction/congestion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethmoid Sinus Obstruction</title>
          <description>Estimated visually based on endoscopic examination on a scale of 0% (no obstruction) to 100% (complete obstruction of the ethmoid cavity by polyps, edema, and/or scarring).</description>
          <units>percent of obstruction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="22.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Implant-Related Serious Adverse Events</title>
        <description>Evaluated via tabulation of implant-related serious adverse events (SAE) reported by subjects between consent and Day 365.</description>
        <time_frame>365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S8 Sinus Implant</title>
            <description>Corticosteroid-eluting Sinus Implant with 1350 mcg of MF
Mometasone furoate nasal spray (MFNS, 200 mcg) once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Implant-Related Serious Adverse Events</title>
          <description>Evaluated via tabulation of implant-related serious adverse events (SAE) reported by subjects between consent and Day 365.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SNOT-22 Total Score</title>
        <description>Sino-Nasal Outcomes Test (SNOT-22) is a validated disease-specific symptom-scoring instrument consisting of 22 questions, each scored on a 6-point scale of 0 (no problem) to 5 (probably as bad as it can be) based on the subject's recollection of symptoms over the past 2 weeks. The total score ranges from 0 to 110, with a higher score reflecting greater symptom burden. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value from baseline. Negative values for change from baseline indicate reduction (improvement) in sino-nasal symptoms.</description>
        <time_frame>Baseline, 90 days, 180 days</time_frame>
        <population>Analysis population includes subjects with available data at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>S8 Sinus Implant</title>
            <description>Corticosteroid-eluting Sinus Implant with 1350 mcg of MF
MFNS (200 mcg) once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>SNOT-22 Total Score</title>
          <description>Sino-Nasal Outcomes Test (SNOT-22) is a validated disease-specific symptom-scoring instrument consisting of 22 questions, each scored on a 6-point scale of 0 (no problem) to 5 (probably as bad as it can be) based on the subject's recollection of symptoms over the past 2 weeks. The total score ranges from 0 to 110, with a higher score reflecting greater symptom burden. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value from baseline. Negative values for change from baseline indicate reduction (improvement) in sino-nasal symptoms.</description>
          <population>Analysis population includes subjects with available data at that time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Obstruction/Congestion Score</title>
        <description>Determined on a scale of 0 (no symptoms) to 3 (severe symptoms) based on the subject's recollection of symptoms over the past week using a reflective paper questionnaire. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value at baseline. Negative values for change from baseline to follow-up indicate reduction (improvement) in nasal obstruction/congestion.</description>
        <time_frame>Baseline, 90 days, 180 days</time_frame>
        <population>Analysis population includes subjects with available data at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>S8 Sinus Implant</title>
            <description>Corticosteroid-eluting Sinus Implant with 1350 mcg of MF.
MFNS (200 mcg) once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Obstruction/Congestion Score</title>
          <description>Determined on a scale of 0 (no symptoms) to 3 (severe symptoms) based on the subject's recollection of symptoms over the past week using a reflective paper questionnaire. Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value at baseline. Negative values for change from baseline to follow-up indicate reduction (improvement) in nasal obstruction/congestion.</description>
          <population>Analysis population includes subjects with available data at that time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from enrollment through Day 365.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>S8 Sinus Implant</title>
          <description>Corticosteroid-eluting Sinus Implant with1350 mcg MF.
MFNS (200 mcg) once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small intestine obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>brain hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>acute sinusitis</sub_title>
                <description>implant-related adverse event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <description>implant-related adverse event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>nasal discomfort</sub_title>
                <description>implant-related adverse event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>rhinalgia</sub_title>
                <description>implant-related adverse event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Stambaugh, Vice President of Clinical &amp; Medical Affairs</name_or_title>
      <organization>Intersect ENT, Inc.</organization>
      <phone>650-641-2103</phone>
      <email>jstambaugh@intersectent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

